The Whisper Becomes a Roar: Why Novartis Needs Avidity’s RNA Revolution, Now More Than Ever
The Silence After the Storm: Ro's New Scale Tackles the Relentless 'Food Noise'
The Long Road to Hope: Anavex's Alzheimer's Drug Hits a Regulatory Wall
Beyond the Pandemic: Moderna's Ambitious Bet on mRNA as the Next Big Cancer Weapon
A Major Setback: Moderna's Highly Anticipated CMV Vaccine Fails Key Efficacy Goal in Phase 3
The Rx Revolution: How Startups Are Rewriting the Rules of Drug Affordability
Another Heartbreak in the Fight Against Dementia: Alector's Flagship Drug Fails Late-Stage Trial
The Dawn of a New Era: How cT-DNA Blood Tests Are Transforming Cancer Surveillance
Gilead Halts HIV Drug Price Hikes Amidst Growing Scrutiny and Public Pressure
The AMA's Bold Stance: Navigating the Future of AI Regulation in Medicine
Beyond Vaccines: Moderna Co-Founder Warns of Widespread Attacks on Science
A Landmark Clash: India's Supreme Court Navigates Life-Saving SMA Drugs, Patents, and Public Access
Beyond COVID: mRNA Vaccines Unleash a New Weapon Against Cancer's Toughest Foes
A New Dawn for Early Breast Cancer: Enhertu's Groundbreaking Impact Revealed at ESMO 2025
A New Dawn for Breast Cancer Treatment: Roche's Gedatolisib and Giredestrant Combination Shows Promise
FDA Unleashes Game-Changing Incentive: Priority Review Vouchers Set to Revolutionize Drug Development
The Revolving Door: Ex-FDA Regulators Find New Homes at Pharma Giants Like Eli Lilly
A Looming Crisis: Funding Cuts Threaten Revolutionary Cancer Immunotherapy Breakthroughs
North Carolina's Biotech Boom: Powering the Future of Medicine Through Advanced Manufacturing
The Dawn of Precision: How Biomarkers are Revolutionizing Dementia Diagnosis
Under Siege: Whistleblowers Unmask Political Pressures Threatening FDA's Scientific Soul
The Production Predicament: How Manufacturing Woes Threaten Novo Nordisk's Blockbuster Drugs
AI to the Rescue? Mass General Brigham's Bold Plan to Combat the Primary Care Doctor Shortage
Unlocking Tomorrow's Cures: Bristol Myers Squibb's Daring Dive into Next-Gen Autoimmune Cell Therapies
Boston-Cambridge: The Unrivaled Epicenter of Global Biotech Innovation
Monopar's Breakthrough in Wilson Disease: A New Dawn with AstraZeneca's Shadow
Biohaven's Breakthrough Bid: Navigating FDA Flexibility for Spinocerebellar Ataxia's Future
The Silent Revolution: AI Scribes Are Listening—Are We Ready for the Ethical Echoes?
The High-Stakes Battle Over Elevidys: Efficacy, Ethics, and the Future of Rare Disease Drugs
A New Chapter: Peter Marks, Former FDA Vaccine Czar, Lands at Eli Lilly
The Ripple Effect: Trump's Autism Claims Ignite a Surge in Tylenol Alternatives
A Dark Day for Science: HHS Dismantles Crucial Bioethics and Science Advisory Boards
The Telehealth Tsunami: Unlocking Healthcare's Future with 50-State Doctor Licensing
The Great Pharmaceutical Reversal: Onshoring's Costly Gamble with Drug Affordability
Europe's Bold New Pharma Gambit: A High-Stakes Bet on Access Over Profit?
The Alarming Pivot: How Telehealth Giants Are Trading Patient Access for Pharmaceutical Profits
Unlocking Autism's Enigma: NIH Launches Groundbreaking Data Science Initiative with a Focus on Exposomics
Crucial Medicare Drug Price Loophole Fix Stalled: A Setback for Patient Savings
Biotech's Q4 Reckoning: Navigating the Storm, Charting the Future
Unveiling the Maternal Research Gap: Why Pregnant Women Need to Be Included in Clinical Trials
The Pharmaceutical Tsunami: How a Second Trump Term Could Reshape Drug Pricing, Medicare, and Vaccines
Healthcare's Brink: How a Government Shutdown Threatens HHS, CDC, and FDA
The Mind Behind Miracles: Daniel Skovronsky's Blueprint for Eli Lilly's R&D Revolution